Released Nov 9, 2026, before the open
10-Q filed Nov 9, 2026, 40 days after period end · 0000874015-26-000271
CARLSBAD, Calif., November 9, 2026 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the third quarter ended September 30, 2026.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $242.72M | $156.72M | $133.81M | $144.21M |
| Net Income | -$109.97M | -$128.61M | -$140.48M |
Ionis Pharmaceuticals Inc · CIK 874015 · Engraved from SEC EDGAR
| -$147.41M |
| EPS Diluted | -$0.66 | -$0.80 | -$0.95 | -$1.03 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ionis reported that third quarter 2026 revenue increased 55% and nine-month revenue increased 64% compared to the same periods last year, excluding the one-time sapablursen upfront payment recognized in the second quarter of 2025.¶2
Cash, cash equivalents and short-term investments decreased to $1.9 billion as of September 30, 2026, from $2.7 billion on December 31, 2025, primarily due to repayment of the 0% convertible notes on April 1, 2026 and cash used to fund operations.¶3